For the year ending 2025-12-31, PBYI has $216,302K in assets. $85,962K in debts. $29,635K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 29,635 | |||
| Marketable securities | 67,893 | |||
| Accounts receivable, net of allowance for credit loss of 0 and 362 | 53,654 | |||
| Inventory | 5,515 | |||
| Prepaid expenses, current | 3,642 | |||
| Restricted cash, current | 2,091 | |||
| Other assets, current | 256 | |||
| Total current assets | 162,686 | |||
| Lease right-of-use assets, net | 5,373 | |||
| Property, plant and equipment, gross | 4,785 | |||
| Less accumulated depreciation | 4,598 | |||
| Property and equipment, net | 187 | |||
| Intangible assets, net | 41,392 | |||
| Restricted cash, long-term | 0 | |||
| Deferred tax assets | 3,830 | |||
| Prepaid expenses and other, long-term | 2,834 | |||
| Total assets | 216,302 | |||
| Accounts payable | 5,056 | |||
| Accrued expenses, current | 50,031 | |||
| Lease liabilities, current | 1,314 | |||
| Post-marketing commitment liability | 2,187 | |||
| Current portion of long-term debt | 22,523 | |||
| Other liabilities, current | 142 | |||
| Total current liabilities | 81,253 | |||
| Lease liabilities, long-term | 4,709 | |||
| Post-marketing commitment liability, long-term | 0 | |||
| Total long-term debt, net | 0 | |||
| Other liabilities, long-term | 0 | |||
| Total liabilities | 85,962 | |||
| Common stock - .0001 par value per share 100,000,000 shares authorized 50,408,023 shares issued and outstanding at december 31, 2025 and 49,105,834 issued and outstanding at december 31, 2024 | 5 | |||
| Additional paid-in capital | 1,414,074 | |||
| Accumulated other comprehensive income | 36 | |||
| Accumulated deficit | -1,283,775 | |||
| Total stockholders equity | 130,340 | |||
| Total liabilities and stockholders equity | 216,302 | |||
PUMA BIOTECHNOLOGY, INC. (PBYI)
PUMA BIOTECHNOLOGY, INC. (PBYI)